Roche CEO Sees Good Demand for New Medicines

The transcript covers a discussion on investor confidence, portfolio strength, and the company's M&A strategy, focusing on smaller acquisitions to complement their portfolio. It addresses potential impacts of Brexit and trade wars on supply chains, emphasizing confidence in maintaining supply. The conversation concludes with a future outlook on healthcare advancements and the company's role in contributing to these developments.

What factors have contributed to the increase in confidence level mentioned in the text?

How has the company's portfolio changed in terms of new medicines and pipeline strength?

What is the company's approach to mergers and acquisitions as described in the text?

How does the company plan to address potential challenges from a hard Brexit?

What is the company's perspective on the impact of a trade war on pharmaceutical supply chains?